氯吡格雷联合阿托伐他汀治疗脑梗死效果和不良反应分析

Efficacy and Side Effects of Clopidogrel Combined with Atorvastatin in the Treatment of Cerebral Infarction

目的:探究氯吡格雷联合阿托伐他汀钙对脑梗死的治疗效果及安全性。方法:选取2018年4月到2019年11月期间我院神经内科收治100例脑梗死患者,以抽签法随机将患者分为对照组及观察组,每组50人。两组均行常规治疗,对照组在常规治疗基础上口服硫酸氢氯吡格雷片,研究组在对照组基础上口服阿托伐他汀钙片,对比两组患者治疗效果,统计并对比患者治疗前后的神经功能缺损(NIHSS)评分,统计两组不良反应情况。结果:对照组疗效为82%(23例显效+18例有效),显著低于研究组的98%(26例显效+23例有效)(P<0.05);组间NIHSS评分治疗前无差异(P>0.05),治疗后均改善且研究组更佳(P<0.05);对照组不良反应发生率(7例,14%)高于研究组患者(1例,2%)(P<0.05)。结论:对于脑梗死患者的治疗来说,氯吡格雷联合阿托伐他汀的应用可获得理想效果,且有较高安全性。

Objective:To explore the efficacy and safety of clopidogrel combined with atorvastatin calcium in the treatment of cerebral infarction.Methods:From April 2018 to November 2019,100 patients with cerebral infarction were randomly divided into two groups:control group and observation group.Both groups were treated with routine therapy,the control group was treated with clopidogrel bisulfate tablets on the basis of routine therapy,the study group was treated with atorvastatin calcium tablets on the basis of the control group,the treatment effect of the two groups was compared,the NIHSS(neurological deficit)score before and after treatment was counted and compared,and the adverse reactions of the two groups were counted.Results:The curative effect of the control group was 82%,which was significantly lower than 98%of the study group(P<0.05);there was no difference in NIHSS score between the groups before treatment(P>0.05),which was improved after treatment and better in the study group(P<0.05);the incidence of adverse reactions in the control group(7 cases,14%)was higher than that in the study group(1 case,2%)(P<0.05).Conclusion:For the treatment of cerebral infarction,the application of clopidogrel combined with atorvastatin can achieve ideal results,and has a high safety,so it can be applied and promoted.